Key Insights

Highlights

Success Rate

86% trial completion

Published Results

56 trials with published results (21%)

Research Maturity

168 completed trials (64% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

10.7%

28 terminated out of 262 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

26%

69 trials in Phase 3/4

Results Transparency

33%

56 of 168 completed with results

Key Signals

56 with results86% success28 terminated

Data Visualizations

Phase Distribution

234Total
Not Applicable (96)
Early P 1 (5)
P 1 (15)
P 2 (49)
P 3 (25)
P 4 (44)

Trial Status

Completed168
Unknown36
Terminated28
Recruiting12
Withdrawn10
Not Yet Recruiting4

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 168 completed trials

Clinical Trials (262)

Showing 20 of 20 trials
NCT07738744Not ApplicableCompleted

A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Liver and Digestive Health

NCT06755970Not ApplicableCompleted

ICOUGH Bundle and Postoperative Pain and Nausea After Laparoscopic Cholecystectomy

NCT07169851Phase 2RecruitingPrimary

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT06740812Phase 4Not Yet Recruiting

Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide

NCT06543316Not ApplicableRecruiting

Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment

NCT05282706Phase 1Completed

Use of Aromatherapy in Conjunction With Physical/Occupational Therapy in an Acute Care Setting

NCT06382012Phase 2Recruiting

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

NCT07328477Not ApplicableCompleted

Box Breathing for Anxiety, Pain and Nausea in ERCP Patients

NCT06464926Not ApplicableRecruitingPrimary

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

NCT02466984Phase 3CompletedPrimary

Subcutaneous Route and Pharmacology of Metoclopramide

NCT07208305Phase 3RecruitingPrimary

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

NCT07523230Not ApplicableCompletedPrimary

Effect of Antiemetic Timing on Nausea Severity and Patient Comfort in the Emergency Department

NCT03593811Early Phase 1CompletedPrimary

Noninvasive Markers of Functional Nausea in Children

NCT04449315Not ApplicableCompleted

Outpatient Oncology Aromatherapy for Symptom Management

NCT07378839Not ApplicableRecruiting

Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting

NCT01440465Completed

Management of Nausea and Vomiting Chemotherapy-induced in Normandy

NCT05819619Early Phase 1TerminatedPrimary

Prophylactic Analgesic and Antiemetic Regimen for Medical Abortion < 70 Days

NCT03118986Phase 2Recruiting

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

NCT05418244Phase 2Recruiting

Inhaled Isopropyl Alcohol for Treatment of Nausea

NCT06439121Not ApplicableCompleted

The 4-7-8 Breathing Technique on Pain and Nausea-Vomiting

Scroll to load more

Research Network

Activity Timeline